Size : 50mg
Synonyms: MK-906
| Description | Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM. |
| Targets & IC50 | 5α reductase:10. nM(Ki) |
| In vitro | After 4, 9, 14, and 21 days, rat prostates were excised to measure androgen and DNA content and to undergo histological and morphological analyses. On day 21, finasteride levels decreased by 65%. Finasteride treatment induced a dose-dependent increase in the incidence of hypospadias (penischisis) in male offspring, with a threshold dose level of approximately 0.1 mg/kg/day and a 100% effect level at 100 mg/kg/day (administered on gestational day 20). Additionally, finasteride reduced the anogenital distance in male offspring rats. After 4 days of treatment with finasteride, DNA content was almost unaffected, but a decrease of up to 52% was observed at 14 days. After prostate sections were stained, 23% of epithelial cells displayed markers of apoptotic cell death on day 14, returning to control levels by day 21. Finasteride caused 16% of epithelial cells to stain for tissue transglutaminase on day 9, with a return to baseline by day 14. Finasteride-induced staining was less intense at 4 days, peaking at 0.7% of epithelial cells and returning to control values by day 9. |
| In vivo | Finasteride inhibits the growth rate of prostate lymph node carcinoma cell lines in a dose-dependent manner and significantly suppresses the secretion and expression of prostate-specific antigen in LNCaP cells. It forms a ternary complex with the reduced coenzyme II of type 2 isoenzyme (Ki: 1.19 nM), which then rearranges into a high-affinity complex (E:Ⅰ) with an approximate first-order rate constant of 1.62ms. |
| Synonyms | MK-906 |
| Molecular Weight | 372.54 |
| Formula | C23H36N2O2 |
| Cas No. | 98319-26-7 |
| Smiles | C[C@@]12[C@]([C@]3([C@@]([C@]4(C)[C@@](CC3)(NC(=O)C=C4)16)(CC1)16)16)(CC[C@@H]2C(NC(C)(C)C)=O)16 |
| Relative Density. | 1.065 g/cm3 |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 37.3 mg/mL (100.12 mM), Sonication is recommended. DMSO: 64 mg/mL (171.79 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
